Afficher la couverture 'CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease | Ma, Christopher' en grand format
/5

0 avis

CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease

Archive ouverte

Ma, Christopher | Hanzel, Jurij | Panaccione, Remo | Sandborn, William | d'Haens, Geert | Ahuja, Vineet | Atreya, Raja | Bernstein, Charles | Bossuyt, Peter | Bressler, Brian | Bryant, Robert | Cohen, Benjamin | Colombel, Jean-Frederic | Danese, Silvio | Dignass, Axel | Dubinsky, Marla | Fleshner, Phillip | Gearry, Richard | Hanauer, Stephen | Hart, Ailsa | Kotze, Paulo Gustavo | Kucharzik, Torsten | Lakatos, Peter | Leong, Rupert | Magro, Fernando | Panés, Julian | Peyrin‐biroulet, Laurent | Ran, Zhihua | Regueiro, Miguel | Singh, Siddharth | Spinelli, Antonino | Steinhart, A Hillary | Travis, Simon | van der Woude, C Janneke | Yacyshyn, Bruce | Yamamoto, Takayuki | Allez, Matthieu | Bemelman, Willem | Lightner, Amy | Louis, Edouard | Rubin, David | Scherl, Ellen | Siegel, Corey | Silverberg, Mark | Vermeire, Severine | Parker, Claire | Mcfarlane, Stefanie | Guizzetti, Leonardo | Smith, Michelle | Vande Casteele, Niels | Feagan, Brian | Jairath, Vipul | D’haens, Geert | Steinhart, A. Hillary | van der Woude, C. Janneke

Edité par CCSD ; Elsevier -

International audience. End points to determine the efficacy and safety of medical therapies for Crohn's disease (CD) and ulcerative colitis (UC) are evolving. Given the heterogeneity in current outcome measures, harmonizing end points in a core outcome set for randomized controlled trials is a priority for drug development in inflammatory bowel disease.

Consulter en ligne

Suggestions

Du même auteur

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Archive ouverte | Peyrin-Biroulet, Laurent | CCSD

International audience. Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in pat...

IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

Archive ouverte | Caron, Bénédicte | CCSD

International audience. Clinical trials evaluating biologics and small molecules in patients with ulcerative colitis are predominantly excluding ulcerative proctitis. The objective of the Definition and endpoints fo...

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

Archive ouverte | Guillo, Lucas | CCSD

International audience. Extraintestinal manifestations occur frequently in patients with inflammatory bowel disease (IBD) and remain a diagnostic and therapeutic challenge. The aim of the Endpoints for Extraintestin...

Chargement des enrichissements...